|Home||» Products||» Sofosbuvir 400 Mg And Ledipasvir 90 Mg||» Hepcvir-L|
Hepcvir-L is a combination medicine containing sofosbuvir and ledipasvir as the active ingredients. It is manufactured by Cipla and each of its boxes contains 28 tablets. Its components act as direct antiviral agents against the virus of hepatitis C. Its component lediapsvir acts as HCV NS5B virus inhibitor and prevents this virus from reproducing. Its other component Sofosbuvir is HCV NS5B RNA polymerase inhibitor, which is essential for the replication of virus.
If the overdose occurs then no particular antidote is available for this drug. In this case the patient needs to be examined for the proof of toxicity. Several supportive measures are available for the overdose occurred on the treatment with sofosbuvir-ledipasvir. This comprises the examination of important signs and also of the clinical position of the patient. As ledipasvir is greatly bound with plasma protein, it is doubtful that Hemodialysis will help in its removal. However, it can significantly remove the chief circulating sofosbuvir metabolite, GS-331007 which has an extraction ratio of 53 percent.
Storage and Handling Instructions
This drug should be stored at temperature not more than 30 degrees.
WARNING:- Hepcvir-L should be taken when prescribed by the medical practitioner. Proper guidance of the doctor should be taken while using this drug. Information printed on the leaflet is only for usual educational reasons and does not include all the pharmaceutical or medical advice. For knowing more about the medicine the patients should consult the medical professional.